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Objective: Dyspnea is a defining symptom in the classification and treatment of chronic
obstructive pulmonary disease (COPD). However, the degree of variation in burden among
symptomatic COPD patients and the possible correlates of burden remain unclear. This study
was conducted to characterize patients in Europe currently being treated for COPD according
to the level of dyspnea in terms of sociodemographics, health-related quality of life, work productivity impairment, and health care resource use assessed by patient reports.
Methods: Data were derived from the 5-EU 2013 National Health and Wellness Survey
(N=62,000). Respondents aged $40 years who reported currently using a prescription for
COPD were grouped according to their level of dyspnea as per the Global Initiative for Chronic
Obstructive Lung Disease guidelines and compared on health status (revised Short Form 36
[SF-36]v2), work impairment (Work Productivity and Activity Impairment questionnaire), and
number of health care visits in the past 6 months using generalized linear models with appropriate distributions and link functions.
Results: Of the 768 respondents who met the inclusion criteria, 245 (32%) were considered
to have higher dyspnea (equivalent to modified Medical Research Council score $2). Higher
dyspnea was associated with decrements ranging from 3.9 to 8.2 points in all eight domains of
the SF-36 health profile after adjustment for sociodemographics, general health characteristics,
and length of COPD diagnosis; mental component summary scores and Short Form-6D health
utility scores were lower by 3.5 and 0.06 points, respectively. Adjusted mean activity impairment (55% vs 37%, P,0.001) and number of emergency room visits (0.61 vs 0.40, P=0.030)
were higher in patients with greater dyspnea.
Conclusion: Many European patients with COPD continue to experience dyspnea despite
treatment and at levels associated with notable impairments in the patients’ ability to function
across a multitude of domains. These patients may benefit from more intense treatment of
their symptoms.
Keywords: COPD, dyspnea, health-related quality of life, activity impairment, symptoms
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Patients with chronic obstructive pulmonary disease (COPD) experience significant
overall symptom burden, comparable to that observed in patients diagnosed with
cancer.1 This symptom burden can be associated with impairments in health-related
quality of life (HRQoL),2–4 impaired functioning,5,6 and higher direct7 and indirect
costs.7–9 COPD treatments have shown effectiveness in reducing breathlessness and
improving HRQoL.10–17 However, some patients continue to experience dyspnea
despite treatment.18,19 Moreover, this is critical given that recent studies suggest that
937
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the COPD-associated burden is increasing globally and costs
are increasing in tandem.20,21 The European Lung White
Book estimates that, COPD is responsible for 150,000 deaths
and 1,691,000 disability-adjusted life years lost in Europe,
thus reinforcing the tremendous burden that COPD exerts
on society at large.22 In Europe, COPD is estimated to be
responsible for €48.4 billion in health care costs and lost
productivity each year, including an estimated €25.1 billion
in indirect costs alone.22
Of all the symptoms of COPD, dyspnea is the most
dominant and defining one.1 Dyspnea is defined as a subjective experience of breathing discomfort that consists of
qualitatively distinct sensations that vary in intensity.23 The
discomfort associated with dyspnea has been shown to affect
HRQoL and health status.24–27 In recognition of the prominent
role of dyspnea in the assessment and management of COPD,
the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) strategy recommends the use of patient-reported
severity of dyspnea as part of the patient classification system. The international group recommends the routine use of
screening measures, such as the COPD Assessment Test28
or the modified Medical Research Council (mMRC)29 scale,
to assess dyspnea among patients. Such assessments require
individuals to report the degree of activity that results in
breathlessness (eg, walking up a flight of stairs) and correlate
well with health status30 and longer assessment measures.31
Despite the importance of self-reported dyspnea in the
classification and treatment of COPD, the degree of variation
in burden in patients with symptomatic COPD and the possible
correlates of burden remain unclear. This is particularly true
on an international level, whereby there exists a paucity of
large-scale representative studies. The aim of this study was

to characterize patients in Europe currently being treated for
COPD according to their level of dyspnea in terms of sociodemographics, HRQoL, work productivity impairment, and
health care resource use assessed by patient reports.

Methods
Study population
Data were derived from the 5-EU 2013 National Health and
Wellness Survey (NHWS; N=62,000). The survey sample
was representative of adults in France, Germany, Italy, Spain,
and the UK, in terms of age and gender; all the data were
self-reported. The protocol for the NHWS was reviewed and
approved by Essex Institutional Review Board (Lebanon,
NJ, USA; protocol number KH-NHES-EU13), and all
respondents provided informed consent. In the current study,
respondents aged $40 years and currently receiving prescription medication for COPD, emphysema, and/or chronic bronchitis (hereafter referred to as COPD) were included. Patients
with asthma were excluded from the selected group to ensure
that dyspnea was a symptom of COPD in the respondents
rather than attributable to asthma.
Participants were categorized into lower and higher dyspnea groups using an item based on the mMRC scale and the
GOLD categorization (mMRC levels 0–1 vs $2; see Table 1
for the exact statements).

Study outcomes
Sociodemographic and health characteristics included age,
gender, body mass index (BMI), current smoking status, and
years since COPD diagnosis. The NHWS asks respondents
to indicate the conditions they have been diagnosed with
from a list of conditions, and these were used to calculate

Table 1 Dyspnea measurement used in GOLD guidelines and the current study
GOLD
classification

mMRC wordinga

Current study wording

Analysis group

Less symptoms

0: I only get breathless with strenuous exercise

Lower dyspnea

More symptoms

1: I get short of breath when hurrying on level
ground or walking up a slight hill
2: On level ground, I walk slower than people of
the same age because of breathlessness, or have
to stop for breath when walking at my own pace

I only get breathless after strenuous exercise
I get breathless after moderate exercise
I get breathless when hurrying on level
ground or walking up a slight incline
I walk slower than most people my age due
to my breathing
I sometimes have to stop for breath even
when walking on level ground at my own pace
I stop for breath every few minutes while
walking, even on level ground
I am too breathless to leave the house
None of the above

Excluded

3: I stop for breath after walking about 100 yards
or after a few minutes on level ground
4: I am too breathless to leave the house or I am
breathless when dressing

Higher dyspnea

Note: amMRC scale is used with the permission of the Medical Research Council.
Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council.
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the Charlson Comorbidity Index (CCI).32 Health status of
respondents was assessed through the revised Short Form-36
health questionnaire (SF-36)v2.33 This instrument is designed
to report on eight health concepts (physical functioning, role
physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Two summary
scores were also calculated: physical component summary
(PCS) and mental component summary (MCS) scores. The
current study used the standard norm-based scores for both
the individual health concept scores and the two-component
summary scores as calculated by the scoring software provided by the scale developer. These scores have a mean of
50 and a standard deviation (SD) of 10 for the US population
(no pan-European norms are available for scoring, and scores
based on the US norms are commonly presented regardless of
country).33 Higher scores indicate better HRQoL. The SF-6D
preference-based health utility was also calculated from
the responses to the SF-36v2 using UK general population
values.34 The SF-6D index has interval scoring properties
and yields summary scores on a theoretical scale of 0–1, with
1 indicating full health.
Impairment in work and non-work daily activities due
to health in the past 7 days was assessed using the General
Health version of the Work Productivity and Activity Impairment questionnaire.35 Employed respondents provided data
for absenteeism (percentage of work time missed), presenteeism (percentage of impairment while at work), and overall
work productivity loss (an estimate that combines absenteeism and presenteeism). All respondents indicated their level
of activity impairment (percentage of impairment in daily
activities because of health; this refers to non-work activities
and does not specifically refer to physical activity).
Health care resource use was captured by the number
of health care provider (HCP) visits, emergency room (ER)
visits, and hospitalizations in 6 months prior to the survey.

Analyses
Lower and higher dyspnea groups were compared on sociodemographic characteristics, general health characteristics,
length of COPD diagnosis, and outcomes by using an
independent sample t-test for continuous variables and the
chi-square test for categorical variables.
Subsequently, a series of regression analyses were conducted to compare the outcomes of the two dyspnea groups
while adjusting for covariates. Covariates included country,
age (as a continuous variable), gender, marital status (married or living with partner vs not married), completion of a
university degree (yes or no), employment status (full-time,
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part-time, or self-employed vs unemployed), household
income (median split within country), BMI category (underweight, normal weight, overweight, obese, or decline to
answer), smoking (current smoker, former smoker, or never
smoked cigarettes), alcohol use (any vs none), exercise (selfreported as the number of days in the past month with vigorous exercise for $20 minutes; coarsened to 0 vs $1 day), CCI
(continuous), and length of COPD diagnosis (continuous).
Linear models were used for HRQoL outcomes, and generalized linear models with a negative binomial distribution
and a log-link function were used for outcomes that were not
normally distributed, including work and activity impairment
as well as health care resource use.

Results
A total of 768 respondents met the inclusion criteria, of
whom 245 (32%) were categorized in the higher dyspnea
group. Those in the higher dyspnea group were less
likely to be employed (P=0.004), more likely to be obese
(BMI $30 kg/m2; P=0.005), less likely to have exercised
in the previous month (P,0.001), and had slightly higher
CCI scores (P=0.012) relative to the respondents with lower
dyspnea (Table 2).
HRQoL was worse among patients with higher dyspnea
than among those with lower dyspnea (Figure 1A). Every
domain and summary score calculated from the SF-36v2 was
lower in patients with higher dyspnea (all P,0.001). The
mean PCS score was 8.4 points lower and the mean MCS
score was 4.1 points lower in patients with higher dyspnea.
The mean health utility score was lower by 0.07 points in
patients with higher dyspnea.
No significant differences in work impairment were
observed between patients with higher and lower dyspnea
(Table 3). Higher dyspnea was associated with a significantly
greater mean impairment in (non-work) daily activities
(65% vs 42%, P,0.001). The difference in the number
of HCP visits did not reach significance (P=0.08). No
statistically significant difference was observed in ER visits
or hospitalizations.

Multivariable results
There were statistically significant decrements in all eight
domains of the SF-36 health profile in the patients with higher
dyspnea after adjustment for sociodemographics, general
health characteristics, and length of COPD (Figure 1B).
Adjusted differences between groups ranged from 3.9 points
for mental health to 8.2 points for the physical functioning subscale. The adjusted mean PCS score was lower by
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Table 2 Characteristics of respondents according to the level of dyspnea
Variables
Country (%)
France
Germany
UK
Italy
Spain
Age in years, mean (SD)
Female (%)
Married/living with partner (%)
University degree (%)
Employed (%)
Household income (%)
Below median
Above median
Decline to answer
BMI categories (%)
Underweight (,18.5 kg/m2)
Normal (18.5 to ,25 kg/m2)
Overweight (25 to ,30 kg/m2)
Obese ($30 kg/m2)
Decline to answer
Smoking status (%)
Current
Former
Never
Drinks alcohol (%)
Exercise in past 30 days (%)
CCI, mean (SD)
Length of diagnosis in years, mean (SD)

Lower dyspnea (n=523)

Higher dyspnea (n=245)

P-value

13.8
38.0
21.6
13.4
13.2
61.39 (9.78)
41.1
67.5
30.2
34.4

14.3
32.2
27.3
15.9
10.2
62.65 (9.03)
42.4
58.0
24.5
24.1

0.206

61.4
29.6
9.0

63.7
27.8
8.6

0.828

2.9
33.7
38.8
23.9
0.8

1.6
28.6
31.8
36.3
1.6

0.005

40.0
41.5
18.5
72.5
46.5
1.76 (1.26)
10.28 (11.80)

34.3
52.2
13.5
68.6
30.6
2.03 (1.71)
11.58 (11.84)

0.016

0.089
0.725
0.010
0.101
0.004

0.266
,0.001
0.012
0.158

Note: P-value is calculated from the independent-samples t-test for the difference between means and from the chi-square test for the differences in proportion.
Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; SD, standard deviation.

6.9 points, whereas the adjusted mean MCS score was lower
by 3.5 points. After adjustment, SF-6D health utilities were
0.06 points lower in higher dyspnea patients than in lower
dyspnea patients.
Activity impairment was considerably greater among
patients with higher dyspnea after adjustment (P,0.001).
Consistent with the unadjusted results, differences in
regression-adjusted work impairment did not reach statistical
significance (all P.0.05; Table 4). Total HCP visits and hospitalizations did not differ according to the level of dyspnea
in unadjusted comparisons, although regression indicated
an association of greater dyspnea with more self-reported
ER visits (P,0.05).

Discussion
In the current study, approximately one in three patients currently using a prescription medication for COPD reported
levels of dyspnea consistent with symptomatic COPD
according to GOLD strategy (mMRC $2). More severe
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self-reported dyspnea was associated with significant impairments in general HRQoL and work productivity, and these
decrements in HRQoL exceeded the 5-point threshold generally considered as the minimally important difference (MID)
for general health, physical functioning, role emotional, role
physical, and social functioning components of the 8-factor
health profile. In addition, both the MCS and PCS scores
exceeded the MID of 3 points, with adjusted difference in
PCS score being more than twice the MID.33 Impairment in
daily activities was also markedly greater among patients
with higher dyspnea, by 18% in absolute terms, and nearly
50% in relative terms. Finally, those with higher dyspnea
also reported higher rates of ER visits compared to those
with lower dyspnea after adjustment for covariates.
The proportion of patients with significant dyspnea
observed in this study is comparable or slightly lower than
that in the European countries included in the Continuing to
Confront COPD survey.36 This survey included respondents
not using a prescription for COPD and did not exclude
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Figure 1 (A) Functional health status and health utility scores by the level of dyspnea (unadjusted). (B) Functional health status and health utility by the level of dyspnea
after regression adjustment.
Notes: *P,0.01; **P,0.001.
Abbreviations: BP, bodily pain; GH, general health; MCS, mental component summary; MH, mental health; PCS, physical component summary; PF, physical functioning;
RE, role emotional; RP, role physical; SF, social functioning; SF-6D, Short Form-6D health utility; VT, vitality.

Table 3 Work impairment and health care use by the level of dyspnea
Lower dyspnea (n=523)

Higher dyspnea (n=245)

Mean (SD)

Mean (SD)

Absenteeism (178 and 58)
Presenteeism (168 and 56)
Overall work impairment (178 and 58)
Activity impairment (%)

12.5 (26.5)
31.9 (29.6)
37.7 (34.1)
42.3 (31.3)

13.9 (26.1)
38.0 (27.9)
43.7 (32.8)
64.8 (27.1)

0.732
0.170
0.240
,0.001

Health care use (prior to 6 months)
HCP visits
ER visits
Hospitalizations

9.0 (8.41)
0.39 (1.57)
0.27 (0.68)

10.20 (9.52)
0.50 (1.33)
0.36 (0.84)

0.082
0.326
0.112

P-value

Work impairment, % (N = L and H dyspnena)

Abbreviations: ER, emergency room; H, higher; HCP, health care provider; L, lower; SD, standard deviation.
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Table 4 Regression-adjusted impairment and health care use by the level of dyspnea
Lower dyspnea (n=523)

Higher dyspnea (n=245)

Mean

SE

Mean

SE

Work impairment
Absenteeism (%)
Presenteeism (%)
Overall work impairment (%)
Activity impairment (%)

6.1
25.5
31.6
36.8

3.0
5.2
6.3
2.5

7.9
35.0
40.3
54.7

4.7
8.1
9.0
4.2

0.562
0.055
0.118

Health care use (prior to 6 months)
HCP visits
ER visits
Hospitalizations

8.0
0.40
0.00

0.7
0.09
0.00

8.4
0.61
0.00

0.9
0.16
0.00

0.438
0.030
0.538

P-value

,0.001

Abbreviations: ER, emergency room; HCP, health care provider; SE, standard error of the mean.

individuals with comorbid asthma, suggesting that it could
have included some individuals whose dyspnea would have
been resolved with medication or may be attributable to
asthma. These new data suggest that the high rate of dyspnea
among COPD patients is present despite treatment and is not
attributable to asthma.
Our findings also provide further confirmation of the
relationship between dyspnea and HRQoL. A recent study
has shown that dyspnea can be a strong predictor of mental
and physical outcome components of HRQoL, even more so
than the objective measures of lung functioning.37 Indeed, a
meta-analysis of the correlation between factors associated
with disease-specific HRQoL as measured by the St George’s
Respiratory Questionnaire among COPD patients indicated
dyspnea as one of the key correlates of HRQoL,38 and the
general relationship between dyspnea and HRQoL has been
demonstrated in a variety of studies ranging from longitudinal
studies incorporating interviewer-administered scales39 as
well as the mMRC and other self-report scales.25,40–42 A particular contribution of the current study is the assessment of
the relationship between dyspnea and the full 8-factor health
profile of the SF-36v2, in addition to the more commonly
reported summary measures derived from the instrument.
The generic, rather than disease-specific, nature of the
SF-36v2 also provides measures that can be compared across
conditions, providing context to the nature and extent of the
impairment relative to other diseases.
The demographic characteristics of patients with COPD
did not differ markedly based on severity of dyspnea, although
individuals who reported higher levels of dyspnea tended to
be more often obese and were less likely to be currently
employed. As such, the decrements in outcomes associated
with dyspnea observed in the unadjusted comparisons are not
likely to be due to group differences in personal characteristics. The groups continued to differ after adjustments for
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a broad range of sociodemographic and health characteristics,
including BMI, comorbid medical conditions, and exercise,
but as weight gain and lack of exercise may actually be the
result of lower levels of physical activity due to dyspnea, the
adjusted comparisons may be overly conservative.

Limitations
While the current study provides important insight into the
experience of COPD sufferers in Europe using a large-scale
representative survey, it is important to note the study limitations. The cross-sectional design of this study did not allow
for causal attributions, although it seems much more likely
that dyspnea is responsible for the decrements in HRQoL
than vice versa, and the relationship between dyspnea and
HRQoL remained after controlling for covariates. Likewise,
previous longitudinal research suggests dyspnea leads to
lower HRQoL across multiple domains.39 Furthermore,
the survey methodology employed did not enable patients’
diagnosis of COPD to be confirmed, nor was information
on patients’ treatment history or objective measures of lung
functioning available. It is also possible that some of the
dyspnea experienced by patients is attributable to conditions
other than COPD, such as congestive heart failure, though
congestive heart failure was reported by a small minority of
the respondents (11% and 4% of those with and without dyspnea, respectively; data not presented) and was included in
the regression analysis through the CCI. These limitations, as
well as the possible recall bias among the study participants,
suggest caution in drawing firm conclusions.

Conclusion
The findings of this study highlight the need for a complete
assessment of dyspnea in patients with COPD. This is important, as this symptom is associated with notable impairments
in the patients’ ability to function across a multitude of

International Journal of COPD 2017:12
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HRQoL domains. This is especially important in the context
of patients with COPD because, many European patients in the
current study continued to experience dyspnea despite being
treated with a prescription medication for it. The results of this
study suggest that many patients experience higher levels of
dyspnea despite treatment and that additional therapies and/or
more intense treatment regimens should be considered.
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